Author response to Cunha et al

The need to identify biomarkers to predict immunotherapy response for rare cancers has been long overdue. We aimed to study this in our paper, ‘Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers’. In this response to the Letter to the Editor by Cunha et a...

Descripción completa

Detalles Bibliográficos
Autores principales: Colen, Rivka R, Rolfo, Christian, Ak, Murat, Ayoub, Mira, Ahmed, Sara, Elshafeey, Nabil, Mamindla, Priyadarshini, Zinn, Pascal O, Ng, Chaan, Vikram, Raghu, Bakas, Spyridon, Peterson, Christine B, Rodon Ahnert, Jordi, Subbiah, Vivek, Karp, Daniel D, Stephen, Bettzy, Hajjar, Joud, Naing, Aung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317086/
https://www.ncbi.nlm.nih.gov/pubmed/34315823
http://dx.doi.org/10.1136/jitc-2021-003299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317086/
https://www.ncbi.nlm.nih.gov/pubmed/34315823
http://dx.doi.org/10.1136/jitc-2021-003299

Ejemplares similares